Impact of prior treatment on patients with relapsed multiple
myeloma treated with carfilzomib and dexamethasone vs
bortezomib and dexamethasone in the phase 3 ENDEAVOR study

MOREAU, P., D. JOSHUA, W.-J. CHNG, A. PALUMBO, H. GOLDSCHMIDT, R. HÁJEK, T. FACON, H. LUDWIG, Luděk POUR, R. NIESVIZKY, A. ORIOL, L. ROSIÑOL, A. SUVOROV, G. GAIDANO, T. PIKA, K. WEISEL, V. GORANOVA-MARINOVA, H.H. GILLENWATER, N. MOHAMED, S. AGGARWAL, S. FENG and M.A. DIMOPOULOS. Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study. Leukemia. London: Nature Publishing Group, 2017, vol. 31, No 1, p. 115-122. ISSN 0887-6924. Available from: https://dx.doi.org/10.1038/leu.2016.186.

Other formats: BibTeX LaTeX RIS

TY  - JOUR
ID  - 1369191
AU  - Moreau, P. - Joshua, D. - Chng, W.-J. - Palumbo, A. - Goldschmidt, H. - Hájek, R. - Facon, T. - Ludwig, H. - Pour, Luděk - Niesvizky, R. - Oriol, A. - Rosiñol, L. - Suvorov, A. - Gaidano, G. - Pika, T. - Weisel, K. - Goranova-Marinova, V. - Gillenwater, H.H. - Mohamed, N. - Aggarwal, S. - Feng, S. - Dimopoulos, M.A.
PY  - 2017
TI  - Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study
JF  - Leukemia
VL  - 31
IS  - 1
SP  - 115-122
EP  - 115-122
PB  - Nature Publishing Group
SN  - 08876924
KW  - 2ND-GENERATION PROTEASOME INHIBITOR
KW  - STEM-CELL TRANSPLANTATION
KW  - LENALIDOMIDE MAINTENANCE
KW  - RETREATMENT
UR  - http://dx.doi.org/10.1038/leu.2016.186
L2  - http://dx.doi.org/10.1038/leu.2016.186
N2  - The randomized phase 3 ENDEAVOR study (N=929) compared carfilzomib and dexamethasone (Kd) with bortezomib and dexamethasone (Vd) in relapsed multiple myeloma (RMM). We performed a subgroup analysis from ENDEAVOR in patients categorized by number of prior lines of therapy or by prior treatment. Median progression-free survival (PFS) for patients with one prior line was 22.2 months for Kd vs 10.1 months for Vd, and median PFS for patients with greater than or equal to2 prior lines was 14.9 months for Kd vs 8.4 months for Vd. For patients with prior bortezomib exposure, the median PFS was 15.6 months for Kd vs 8.1 months for Vd, and for patients with prior lenalidomide exposure the median PFS was 12.9 months for Kd vs 7.3 months for Vd. Overall response rates (Kd vs Vd) were 81.9 vs 65.5% (one prior line), 72.0 vs 59.7% (greater than or equal to2 prior lines), 71.2 vs 60.3% (prior bortezomib) and 70.1 vs 59.3% (prior lenalidomide). The safety profile in the prior lines subgroups was qualitatively similar to that in the broader ENDEAVOR population. In RMM, outcomes are improved when receiving treatment with carfilzomib compared with bortezomib, regardless of the number of prior therapy lines or prior exposure to bortezomib or lenalidomide.
ER  -

Basic information
Original name	Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study
Authors	MOREAU, P., D. JOSHUA, W.-J. CHNG, A. PALUMBO, H. GOLDSCHMIDT, R. HÁJEK, T. FACON, H. LUDWIG, Luděk POUR, R. NIESVIZKY, A. ORIOL, L. ROSIÑOL, A. SUVOROV, G. GAIDANO, T. PIKA, K. WEISEL, V. GORANOVA-MARINOVA, H.H. GILLENWATER, N. MOHAMED, S. AGGARWAL, S. FENG and M.A. DIMOPOULOS.
Edition	Leukemia, London, Nature Publishing Group, 2017, 0887-6924.

Other information
Original language	English
Type of outcome	Article in a journal
Field of Study	30205 Hematology
Country of publisher	United Kingdom of Great Britain and Northern Ireland
Confidentiality degree	is not subject to a state or trade secret
WWW	URL
Impact factor	Impact factor: 10.023
Organization unit	Faculty of Medicine
Doi	http://dx.doi.org/10.1038/leu.2016.186
UT WoS	000394058700015
Keywords in English	2ND-GENERATION PROTEASOME INHIBITOR; STEM-CELL TRANSPLANTATION; LENALIDOMIDE MAINTENANCE; RETREATMENT
Tags	EL OK
Tags	International impact, Reviewed
Changed by	Changed by: Soňa Böhmová, učo 232884. Changed: 16/3/2018 16:59.

Abstract

The randomized phase 3 ENDEAVOR study (N=929) compared carfilzomib and dexamethasone (Kd) with bortezomib and dexamethasone (Vd) in relapsed multiple myeloma (RMM). We performed a subgroup analysis from ENDEAVOR in patients categorized by number of prior lines of therapy or by prior treatment. Median progression-free survival (PFS) for patients with one prior line was 22.2 months for Kd vs 10.1 months for Vd, and median PFS for patients with greater than or equal to2 prior lines was 14.9 months for Kd vs 8.4 months for Vd. For patients with prior bortezomib exposure, the median PFS was 15.6 months for Kd vs 8.1 months for Vd, and for patients with prior lenalidomide exposure the median PFS was 12.9 months for Kd vs 7.3 months for Vd. Overall response rates (Kd vs Vd) were 81.9 vs 65.5% (one prior line), 72.0 vs 59.7% (greater than or equal to2 prior lines), 71.2 vs 60.3% (prior bortezomib) and 70.1 vs 59.3% (prior lenalidomide). The safety profile in the prior lines subgroups was qualitatively similar to that in the broader ENDEAVOR population. In RMM, outcomes are improved when receiving treatment with carfilzomib compared with bortezomib, regardless of the number of prior therapy lines or prior exposure to bortezomib or lenalidomide.

PrintDisplayed: 1/5/2024 09:38

Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and ...

Other applications